American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Earlier this week, the Financial Times reported activist investor Starboard Value had taken a stake in Becton and was pushing ...

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ...

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

Tesla sales careened lower in Germany in January, as sales of the electric vehicle company headed by Elon Musk tumble across Europe. The TV spot marks the artificial-intelligence company's biggest ...